ACADIA Pharmaceuticals Inc.
ACAD
$25.42
-$0.27-1.05%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.02B | 996.28M | 957.80M | 929.24M | 890.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.02B | 996.28M | 957.80M | 929.24M | 890.53M |
| Cost of Revenue | 405.34M | 401.12M | 385.09M | 347.19M | 433.31M |
| Gross Profit | 613.55M | 595.17M | 572.71M | 582.05M | 457.22M |
| SG&A Expenses | 508.35M | 491.91M | 473.53M | 454.91M | 434.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 913.69M | 893.02M | 858.62M | 802.10M | 867.72M |
| Operating Income | 105.20M | 103.26M | 99.18M | 127.14M | 22.82M |
| Income Before Tax | 267.88M | 264.85M | 258.08M | 136.69M | 45.74M |
| Income Tax Expenses | 45.72M | 35.97M | 31.62M | 8.19M | 15.18M |
| Earnings from Continuing Operations | 222.16 | 228.88 | 226.45 | 128.51 | 30.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 222.16M | 228.88M | 226.45M | 128.51M | 30.57M |
| EBIT | 105.20M | 103.26M | 99.18M | 127.14M | 22.82M |
| EBITDA | 118.87M | 116.57M | 115.06M | 139.44M | 34.27M |
| EPS Basic | 1.33 | 1.38 | 1.36 | 0.78 | 0.18 |
| Normalized Basic EPS | 0.51 | 0.50 | 0.48 | 0.55 | 0.15 |
| EPS Diluted | 1.33 | 1.37 | 1.36 | 0.77 | 0.17 |
| Normalized Diluted EPS | 0.51 | 0.50 | 0.48 | 0.55 | 0.15 |
| Average Basic Shares Outstanding | 667.14M | 664.87M | 662.86M | 661.14M | 659.40M |
| Average Diluted Shares Outstanding | 669.22M | 666.72M | 665.67M | 665.49M | 663.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |